Sprint Bioscience AB (SPRINT.ST) Stock Analysis & Winston Score

Sprint Bioscience is a Swedish biotech company that discovers and develops drug candidates targeting cancer. It focuses on finding small molecules that can block specific proteins involved in tumor growth, then licenses those drug candidates to larger pharmaceutical companies. The company operates in the early-stage drug discovery space, meaning it works on the science before a drug is anywhere close to reaching patients. Sprint Bioscience makes most of its money through licensing deals and research collaborations with bigger pharma and biotech partners, who pay fees and milestone payments when programs hit certain scientific targets. The company is based in Huddinge, Sweden, and is relatively small, with a market cap around $400 million. Its high margins reflect a licensing-based model rather than manufacturing costs, but the core risk is that early-stage drug discovery is highly uncertain — most drug candidates fail before reaching clinical trials, and losing a key partnership deal could significantly impact revenue.